1. HBW Insight
  2. >>Geography
  3. >>Europe

Why Did Germany’s Switch Committee Reject Perrigo’s OTC Daily Contraceptive Proposal?

 
• By David Ridley

Skepticism about the need for widening access to the progestogen-only contraceptive pill, fears of associated thrombosis risk with use and the potential cost barriers were among the many reasons for the unanimous rejection of Perrigo's Rx-to-OTC switch application for desogestrel (75μg) for oral use.

Contraceptive pill
• Source: Shutterstock

Germany’s Expert Committee for Prescription was not convinced of the value of making Perrigo’s progestogen-only contraceptive pill available OTC, according to the recently-published minutes of its 23 January meeting.

Among many concerns which led the committee to unanimously reject Perrigo’s switch application for desogestrel (75μg) for oral use was a skepticism towards a seemingly uncontroversial claim that making the drug OTC would remove a barrier to access for women

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By David Ridley

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By David Ridley

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

More from Geography

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By David Ridley

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

OTCs Are ‘Beacon Of Hope’ For Austrian Pharmacy

 
• By David Ridley

Just under half of Austrian pharmacists surveyed by Elpato Medien are “convinced that the OTC business will ensure the survival of their pharmacy.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.